Nektar Therapeutics (NKTR) PT Raised to $63 at Evercore ISI; 'Highlights from 4Q earnings call'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Nektar Therapeutics (NKTR) PT Raised to $94 at Canaccord Genuity
March 2, 2018 7:24 AM ESTCanaccord Genuity raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $94.00 (from $80.00) while maintaining a Buy rating.
... MoreMizuho Sees Potential Nektar Therapeutics (NKTR) Takeover by Bristol-Myers Squibb (BMY) This Year
March 2, 2018 6:31 AM ESTMizuho Securities analyst Difei Yang believes there is a possibility of a Nektar Therapeutics (NASDAQ: NKTR) take-out in 2018 and new positive clinical data of NKTR-214 in combo with Bristol-Myers Squibb (NYSE: BMY) Opdivo reinforces their... More
Nektar Therapeutics (NKTR) PT Raised to $103 at Jefferies
March 2, 2018 1:01 AM ESTJefferies raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $103.00 (from $88.00) while maintaining a Buy rating.
... More